Generx is a one-time, non-surgical angiogenic gene therapy being developed by Cardium Therapeutics (NYSE Amex: CXM). This new therapeutic approach employs human DNA growth factor to stimulate the hearts natural ability to grow additional blood vessels (angiogenesis) for patients with advanced coronary artery disease and chest pain (angina pectoris). The therapy is in clinical trials and is intended to offer an innovative non-surgical option for cardiac patients who currently undergo surgical procedures such as balloon angioplasty, stents, or open heart cardiac bypass graft surgery (CABG).
Specific information about Generx and Cardium Therapeutics can be found at: cardiumthx.com.
Loading more stuff…
Hmm…it looks like things are taking a while to load. Try again?